PCOS Is Now PMOS: Why the New Name Is More Than a Rebrand

Written by Kerri Rachelle, PhD(c), RDN, CSSD, FMP-AC
Founder & CEO, REV0lution | Doctor of Integrative & Natural Medicine Candidate

Quick Answer

In May 2026, polycystic ovary syndrome, PCOS, was officially renamed polyendocrine metabolic ovarian syndrome, or PMOS. The change followed a multiyear global consensus process involving patients and more than 50 professional and advocacy organizations.

The new name recognizes that this is not simply an ovarian condition defined by “cysts.” PMOS is a complex endocrine, metabolic and reproductive syndrome that can affect ovulation, androgen activity, insulin sensitivity, cardiovascular risk, mental health, skin and fertility.

The name has changed, but the condition is not new, and the diagnostic criteria did not suddenly change on the day of the announcement.

Key Takeaways

• PCOS is now called polyendocrine metabolic ovarian syndrome, or PMOS.

• The old name incorrectly centered ovarian “cysts,” which are neither true cysts nor required in every case.

• “Polyendocrine” recognizes that multiple hormone systems can be involved.

• “Metabolic” brings insulin resistance and long-term cardiometabolic health into clearer focus.

• “Ovarian” preserves the important reproductive and ovulatory features.

• PMOS can occur in women of any body size.

• The name change does not mean everyone with PMOS has insulin resistance or obesity.

• Diagnosis still requires an appropriate clinical evaluation and exclusion of conditions that can produce similar symptoms.

• PMOS care should address the whole person—not simply weight, fertility or birth-control prescriptions.

For decades, the name polycystic ovary syndrome created the wrong first impression.

It suggested that the condition was primarily about cysts on the ovaries. Women were told they could not have PCOS because an ultrasound looked normal. Others were diagnosed because an ultrasound showed multiple follicles, even though ovarian appearance alone did not explain the full clinical picture.

Meanwhile, insulin resistance, metabolic risk, androgen excess, mental health, sleep and long-term cardiovascular health could receive far less attention than fertility or body weight.

In May 2026, a global consensus officially renamed the condition polyendocrine metabolic ovarian syndrome—PMOS. The change was published in The Lancet following a multistep process involving patients, clinicians, researchers and more than 50 professional and advocacy organizations.

This is more than a rebrand. It is an attempt to correct decades of misunderstanding about what the condition is—and what comprehensive care should include.

What Does PMOS Stand For?

PMOS stands for polyendocrine metabolic ovarian syndrome.

Each part of the name expands the clinical picture.

Polyendocrine

“Polyendocrine” recognizes that multiple hormone systems and signaling pathways may be involved. PMOS is not limited to the ovaries.

Relevant features may include:

• Elevated androgen activity

• Irregular ovulation

• Insulin resistance

• Altered reproductive signaling

• Changes in appetite and weight regulation

• Interactions with thyroid, adrenal and other endocrine concerns

This does not mean every hormone is abnormal in every person. It means the syndrome cannot be adequately explained by ovarian appearance alone.

Metabolic

“Metabolic” acknowledges the connection between PMOS and insulin resistance, glucose regulation, lipids, blood pressure and long-term cardiometabolic risk. Understanding what metabolic health means is therefore an important part of understanding PMOS.

Insulin resistance is common in PMOS and can occur in women who are not living in larger bodies. When insulin levels remain elevated, they may contribute to increased ovarian androgen production and reduced sex hormone-binding globulin, increasing the amount of biologically active androgen.

That relationship can contribute to:

• Irregular ovulation

• Menstrual changes

• Acne

• Facial or body hair growth

• Scalp hair thinning

• Difficulty with weight regulation

• Increased risk of prediabetes and type 2 diabetes

However, insulin resistance is not present in exactly the same way in every woman with PMOS. The new name should improve metabolic attention—not replace one oversimplification with another.

Ovarian

“Ovarian” preserves the reproductive component of the condition. PMOS can affect follicle development, ovulation, menstruation and fertility.

The structures historically called “cysts” are generally immature ovarian follicles—not the same as pathological ovarian cysts. Some women with PMOS have polycystic ovarian morphology, while others do not.

Ovarian appearance is one possible feature. It is not the complete syndrome.

Syndrome

A syndrome is a collection of features that can appear in different combinations.

One woman may seek care because of irregular periods and infertility. Another may have acne, hair growth and insulin resistance. Another may be lean, menstruate somewhat regularly and still experience androgen-related symptoms and metabolic risk.

PMOS does not look identical in everyone.

Why Was the Name PCOS So Misleading?

The term “polycystic ovary syndrome” created several persistent myths.

Myth: You Must Have Ovarian Cysts

Ovarian cysts are not required for diagnosis. The ultrasound finding associated with PMOS refers to an increased number of developing follicles or increased ovarian volume—not necessarily pathological cysts.

Myth: A Normal Ultrasound Rules It Out

It does not. An adult can meet diagnostic criteria through ovulatory dysfunction and hyperandrogenism without polycystic ovarian morphology.

Myth: It Is Primarily a Fertility Condition

Fertility is important, but PMOS may also affect glucose regulation, cardiovascular risk, mental health, sleep and quality of life across the lifespan.

A woman should not lose access to meaningful PMOS care simply because she is not currently trying to become pregnant.

Myth: It Only Affects Women in Larger Bodies

PMOS occurs across body sizes. Lean women can experience androgen excess, ovulatory dysfunction and insulin resistance.

Assuming that someone cannot have PMOS because she is thin can delay diagnosis. Assuming that every symptom will resolve if a woman loses weight can also delay comprehensive care.

Did the Diagnostic Criteria Change?

The name changed in 2026, but the condition did not become a different disease overnight. Current adult diagnosis still centers on identifying a combination of:

• Clinical or biochemical hyperandrogenism

• Ovulatory dysfunction

• Polycystic ovarian morphology, with anti-Müllerian hormone used in specific adult diagnostic contexts

Other conditions that can produce similar symptoms must be excluded. Depending on the presentation, evaluation may include consideration of:

• Pregnancy

• Thyroid dysfunction

• Elevated prolactin

• Nonclassic congenital adrenal hyperplasia

• Cushing syndrome

• Androgen-secreting tumors

• Hypothalamic amenorrhea

• Perimenopause

• Medication effects

Adolescents require particular care because irregular cycles, acne and changing ovarian morphology can overlap with normal puberty. Adult ultrasound or hormone rules should not be casually imposed on teenagers. Updated international guidelines incorporating PMOS terminology are expected to evolve over the next several years. Until then, clinicians and patients will likely see both PCOS and PMOS used during the transition.

Why Does the New Name Matter?

Names shape what clinicians look for and what patients believe deserves attention. When “polycystic ovaries” dominate the name, care can become overly focused on ultrasound, menstrual suppression and fertility. When “polyendocrine” and “metabolic” are included, the name directs attention toward the condition’s broader physiology.

A better name may encourage earlier evaluation of:

• Glucose and insulin regulation

• Blood pressure

• Lipids

• Sleep apnea

• Mental health

• Menstrual regularity

• Endometrial health

• Fertility goals

• Androgen-related symptoms

• Long-term cardiovascular risk

The name alone will not improve care. Clinicians must act on what it represents. When testing is warranted, functional medicine laboratory testing should be used to answer a meaningful clinical question—not to order every available marker without a clear purpose.

Is PMOS Caused by Insulin Resistance?

Insulin resistance is an important driver for many women with PMOS, but it is not the sole cause of every case. PMOS appears to involve interactions among genetics, androgen signaling, ovarian function, metabolic health and environmental factors. Different features may dominate in different people. When insulin resistance is present, elevated insulin can amplify ovarian androgen production and worsen metabolic risk. Improving insulin sensitivity may therefore support ovulation, androgen regulation and long-term health. Fasting glucose and A1C do not always reveal the earliest stages of impaired insulin regulation. In some cases, evaluating fasting insulin alongside other clinical information may provide additional context.

That does not mean a woman caused PMOS by eating carbohydrates or gaining weight. It also does not mean she needs to eliminate every carbohydrate. The more useful approach is to evaluate glucose and insulin regulation, build meals around real food, preserve muscle, move regularly, sleep adequately and select whole-food carbohydrates according to the individual. Because PMOS can increase long-term glucose risk, women should also understand what prediabetes is and why relying only on the absence of diabetes symptoms may delay meaningful intervention.

Why Weight Loss Cannot Be the Entire Treatment Plan

Lean women may still experience androgen excess, irregular ovulation, insulin resistance and increased metabolic risk. Higher body fat can intensify metabolic and reproductive symptoms for some women, but it is not required for PMOS and is not always the underlying cause. Genetics, androgen signaling, ovarian function, insulin regulation and other endocrine factors can contribute independently of body size.

Some women with PMOS may benefit metabolically from losing excess body fat, but that does not make “lose weight” an adequate treatment plan. Weight regulation may itself be complicated by insulin resistance, poor sleep, medication effects, appetite dysregulation and hormonal symptoms. Assuming that PMOS only affects women in larger bodies—or telling a woman simply to eat less—can delay diagnosis, overlook the drivers of her symptoms and deny her comprehensive care.

If you have repeatedly wondered, “Why can’t I lose weight?”, the answer may involve far more than willpower or calorie tracking. Care should consider:

• Menstrual and ovulatory function

• Androgen-related symptoms

• Glucose and insulin regulation

• Blood pressure and lipids

• Sleep

• Mental health

• Fertility goals

• Muscle and physical activity

• Food quality

• Medication

• Nutrient status

• Digestive health

• Personal preferences and culture

PMOS exists in lean women too. A treatment model centered entirely on weight will miss them.

What Should You Eat With PMOS?

There is no single PMOS diet. A strong starting template includes recognizable protein, vegetables, fiber-rich plants, naturally occurring fats and individualized whole-food carbohydrates.

Examples include:

• Eggs, fish, poultry, meat or another minimally processed protein

• Leafy greens and colorful vegetables

• Berries and other whole fruit

• Avocado, olives, nuts and seeds

• Potatoes, sweet potatoes, squash and other whole-food carbohydrates selected for the individual

• Fermented foods when tolerated

Carbohydrate quantity and distribution may need adjustment when insulin resistance is present, but PMOS does not require every woman to follow the same low-carbohydrate diet. What REV0lution does not recommend is building PMOS nutrition around:

• Artificially sweetened shakes

• Protein bars as meal replacements

• Packaged keto desserts

• “Zero-sugar” products

• Artificial colors

• Unnecessary preservatives and emulsifiers

• Manufactured flavor systems

Matching calories or carbohydrates does not make an ultra-processed product nutritionally equivalent to real food. Our functional medicine registered dietitians can help connect symptoms, laboratory findings, food quality, glucose regulation and individual preferences without reducing the entire plan to calorie restriction.

Can Intermittent Fasting Help PMOS?

Intermittent fasting may help some women improve meal consistency, reduce late-night eating or address insulin resistance. Early studies are promising, but the evidence is not strong enough to prescribe fasting as a universal PMOS treatment.

Fasting may be unhelpful when it causes:

• Under-fueling

• Intense morning hunger

• Rebound eating

• Menstrual disruption

• Poor sleep

• Food preoccupation

• Inadequate protein

• Declining exercise recovery

The question is not whether fasting is theoretically good for PMOS. It is whether a particular schedule improves the individual woman’s health without compromising nutrition or reproductive function. Women considering fasting should begin with the evidence on intermittent fasting for women, particularly when menstrual function, hormone symptoms, fertility or demanding training are relevant.

If fasting leaves you ravenous, shaky or unable to eat calmly, do not force it. A shorter overnight fast or a consistent meal schedule may be more appropriate than trying to tolerate a rigid fasting target.

Does PMOS Require Medication?

Some women benefit substantially from medication.

Depending on symptoms, metabolic health and fertility goals, care may include medications that support:

• Menstrual regulation

• Endometrial protection

• Insulin sensitivity

• Ovulation

• Androgen-related symptoms

• Weight management

• Fertility

Medication is not evidence that real-food nutrition failed, and it should not be treated as an artificial impurity that must be avoided to practice functional medicine. Nutrition, movement, sleep and medication can work together. Prescribed medication should never be stopped or changed without the appropriate clinician.

The Bottom Line

PCOS is now PMOS: polyendocrine metabolic ovarian syndrome. The new name is more accurate because the condition is not simply about ovarian “cysts.” It can involve multiple endocrine systems, metabolic health, androgen signaling, ovulation, menstruation, fertility, skin, mental health and long-term cardiometabolic risk.

The name change will matter only if it helps patients better understand the underlying drivers of their symptoms—and if care changes with it.

Women deserve more than an ultrasound, a birth-control prescription or the instruction to lose weight. They deserve an evaluation that considers the full endocrine, metabolic and reproductive picture. PMOS is not a new condition. It is a better name for a condition medicine should have been seeing more clearly all along.

Medical Disclaimer: This article is for general educational and informational purposes only and does not provide individualized medical or nutrition advice. It is not intended to diagnose, treat, cure, or prevent disease or replace care from a qualified healthcare professional. Do not change your medications, supplements, diet, fasting schedule, or healthcare plan based solely on this content. [Read the full Medical Disclaimer and Terms & Conditions.]

Medical Disclaimer: This article is for general educational and informational purposes only and does not provide individualized medical or nutrition advice. It is not intended to diagnose, treat, cure, or prevent disease or replace care from a qualified healthcare professional. Do not change your medications, supplements, diet, fasting schedule, or healthcare plan based solely on this content. [Read the full Medical Disclaimer and Terms & Conditions.]

Frequently Asked Questions

Is PCOS officially called PMOS now?

Yes. In May 2026, polycystic ovary syndrome—PCOS—was officially renamed polyendocrine metabolic ovarian syndrome, or PMOS, following a multiyear global consensus process. The transition will take time, so patients will continue to see both PCOS and PMOS used in medical records, research, clinical guidelines and online health information.

What does PMOS stand for?

PMOS stands for polyendocrine metabolic ovarian syndrome. “Polyendocrine” recognizes the involvement of multiple hormone systems. “Metabolic” brings greater attention to insulin resistance, glucose regulation and cardiometabolic health. “Ovarian” preserves the condition’s reproductive and ovulatory features, while “syndrome” reflects the different combinations of symptoms that can occur.

Why was PCOS renamed PMOS?

The name polycystic ovary syndrome was misleading because it suggested that ovarian cysts defined the condition. The structures commonly seen on ultrasound are generally developing ovarian follicles—not pathological cysts—and they are not present or required in every case. The old name also failed to represent the condition’s broader endocrine, metabolic, reproductive and psychological effects. PMOS provides a more accurate description of the whole-body syndrome.

Is PMOS a new condition?

No. PMOS is the new name for the condition previously called PCOS. The renaming does not mean a new disorder was discovered, and women previously diagnosed with PCOS do not need to be rediagnosed solely because the terminology changed.

Did the diagnostic criteria change when PCOS became PMOS?

No immediate diagnostic change occurred solely because of the new name. Current adult diagnosis continues to consider hyperandrogenism, ovulatory dysfunction and polycystic ovarian morphology or anti-Müllerian hormone in specific adult diagnostic contexts. Other conditions that can cause similar symptoms must also be excluded. Updated guidelines incorporating the PMOS terminology are expected as the transition continues.

Do you need ovarian cysts to have PMOS?

No. Ovarian cysts are not required for diagnosis. An adult may meet diagnostic criteria through ovulatory dysfunction and clinical or biochemical hyperandrogenism without polycystic ovarian morphology. A normal ultrasound therefore does not automatically rule out PMOS.

Can you have PMOS if you have regular periods?

Possibly. Apparently regular bleeding does not always confirm that ovulation is occurring normally, and PMOS can present differently among individuals. Someone with androgen-related symptoms, metabolic concerns or other signs of PMOS should receive an individualized evaluation rather than being ruled out based on one feature.

Is PMOS caused by insulin resistance?

Insulin resistance is common in PMOS and can contribute to increased ovarian androgen production, reduced sex hormone-binding globulin and greater metabolic risk. However, it is not the sole cause of every case. PMOS appears to involve interactions among genetics, androgen signaling, ovarian function, metabolic health and environmental influences. Not every woman experiences the same metabolic pattern.

Can you have PMOS without being overweight?

Yes. PMOS occurs across body sizes. Lean women may still experience androgen excess, irregular ovulation, insulin resistance and increased metabolic risk. Assuming that PMOS only affects women in larger bodies can delay diagnosis and appropriate care.

Does PMOS always cause infertility?

No. PMOS can interfere with ovulation and make conception more difficult, but it does not mean pregnancy is impossible. Some women ovulate inconsistently, while others ovulate regularly. Fertility support should be based on the individual’s ovulatory function, age, health history and reproductive goals.

What should you eat with PMOS?

There is no single mandatory PMOS diet. A strong starting point is a minimally processed pattern built around meaningful protein, vegetables, fiber-rich plants, naturally occurring fats and individualized whole-food carbohydrates. REV0lution does not recommend building PMOS nutrition around artificially sweetened shakes, meal-replacement bars, packaged keto desserts, artificial colors, unnecessary preservatives, emulsifiers or manufactured flavor systems. Matching calories or carbohydrates does not make manufactured products equivalent to real food.

Does PMOS require a low-carbohydrate diet?

No. Some women with insulin resistance may benefit from adjusting carbohydrate quantity, quality or distribution, but every woman with PMOS does not need to follow an extremely low-carbohydrate diet. Whole-food carbohydrates can be selected according to insulin sensitivity, activity, sleep, symptoms, medication, menstrual function and individual tolerance.

Can intermittent fasting help PMOS?

Intermittent fasting may help some women establish a more consistent eating rhythm, reduce late-night eating or improve selected metabolic markers. The evidence is not strong enough to prescribe it as a universal PMOS treatment. Fasting should not be forced if it causes intense morning hunger, under-fueling, rebound eating, menstrual disruption, food preoccupation, inadequate protein or poor exercise recovery. Women considering fasting should first understand the evidence on intermittent fasting for women.

Does PMOS require medication?

Not everyone requires the same medication, but some women benefit substantially from it. Depending on symptoms and goals, medication may support menstrual regulation, endometrial protection, insulin sensitivity, ovulation, androgen-related symptoms, weight management or fertility. Medication and real-food nutrition are not opposing philosophies, and prescribed medication should never be stopped or changed without the appropriate clinician.

Is PMOS only a reproductive or fertility condition?

No. PMOS can affect ovulation and fertility, but it may also influence glucose regulation, insulin levels, cardiovascular risk factors, sleep, skin, hair, mental health and quality of life. Comprehensive care should address the complete endocrine, metabolic and reproductive picture—not only pregnancy plans or body weight.

References

Teede HJ, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026. PMID: 42119588.

Dalamaga M, et al. What’s in a name? From PCOS to polyendocrine metabolic ovarian syndrome. 2026. PMID: 42327014.

Kordowitzki P, et al. Polyendocrine metabolic ovarian syndrome—a new name for an old problem. Nat Metab. 2026. PMID: 42237044.

Taieb A, et al. A perspective on renaming polycystic ovary syndrome for patient care and scientific progress. 2024. PMID: 39494232.

Teede HJ, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. 2023;189(2):G43–G64. PMID: 37580314.

Teede HJ, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2023;120(4):767–793. PMID: 37580861.

Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270–284. PMID: 29569621.

Shang Y, et al. Effect of diet on insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod Sci. 2020;27(9):1787–1801. PMID: 32621748.

Kazemi M, et al. Effects of dietary glycemic index and glycemic load on cardiometabolic and reproductive profiles in women with polycystic ovary syndrome: a systematic review and meta-analysis. Adv Nutr. 2021;12(1):161–178. PMID: 32805007.

Moran LJ, et al. Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines. J Acad Nutr Diet. 2013;113(4):520–545. PMID: 23420000.

Gautam R, et al. The role of lifestyle interventions in PCOS management: a systematic review. Nutrients. 2025;17(2):310. PMID: 39861440.

Fitz V, et al. Inositol for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 international evidence-based PCOS guidelines. J Clin Endocrinol Metab. 2024. PMID: 38163998.